168-LB – Burden of Cardiovascular Comorbidity in U.S. Adults with T1D
12:00 p.m. Sunday
Poster Hall (Hall F, North, Exhibition Level)
Recent estimates regarding the burden of cardiovascular disease among U.S. patients with type 1 diabetes are limited. Therefore, we conducted an analysis to evaluate the real-world prevalence and economic impact of cardiovascular comorbidities in a U.S. adult population with type 1 diabetes. The analysis included over 12,000 adults with type 1 diabetes. In this study population, 27 percent and 44 percent of the patients had cardiovascular disease and cardiovascular risk factors, respectively.
Patients with type 1 diabetes and cardiovascular disease or cardiovascular risk factors had significantly higher health-care resource utilization compared with patients with type 1 diabetes who had no cardiovascular disease or risk factors. In addition, we observed more diabetes-related prescription claims among patients with cardiovascular disease.
As a result of increased medical care utilization, the overall annual cost of care per patient with comorbid cardiovascular disease and cardiovascular risk factors was 2.6-times and 1.4-times, respectively, that of patients without cardiovascular disease or risk factors.
In conclusion, our analysis showed that more than one in five adults with type 1 diabetes in the U.S. have cardiovascular disease, and more than two in five have cardiovascular risk factors, which may be indicative of suboptimal control of underlying diabetes. Improved patient outcomes and reduced economic burden of type 1 diabetes can be achieved by better management of the disease and the underlying cardiovascular comorbidities.
Finally, I would like to disclose that this analysis was funded by Sanofi and Lexicon Pharmaceuticals.